{"schema_version":"secwatch.filing_event.v1","accession":"0000886163-23-000047","form_type":"8-K","ticker":"LGND","cik":"0000886163","company_name":"LIGAND PHARMACEUTICALS INC","filed_at":"2023-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:36.883316+00:00","generated_at":"2026-06-12T03:26:21.857984+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Ligand Q2 adjusted EPS $1.42 beats; raises FY2023 adjusted EPS outlook to $4.85-$5.00","bullets":["Q2 adjusted net income from continuing ops $25.1M ($1.42 diluted) vs $7.4M ($0.43) prior year; GAAP EPS $0.13.","Royalties grew 15% to $20.4M; core Captisol sales $5.2M vs $3.3M. No COVID-19 Captisol sales vs $26.2M.","Cash $219M; debt-free after May 2023 convertible note payoff. $50M share repurchase program authorized.","FY2023 guidance: revenue $124-128M (reaffirmed); adjusted EPS raised to $4.85-$5.00 from $4.60-$4.75.","Agreed to purchase Novan assets for $15M cash plus DIP financing; Berdazimer gel NDA PDUFA Jan 5, 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000886163-23-000047","json":"https://secwatch.observer/filing/0000886163-23-000047.json","markdown":"https://secwatch.observer/filing/0000886163-23-000047.md","text":"https://secwatch.observer/filing/0000886163-23-000047.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/886163/000088616323000047/0000886163-23-000047-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/886163/000088616323000047/lgnd-20230808.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T03:26:21.857984+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"08ef8592bd6513f6244a36ed26b0d565badeaf2f","claim":"LIGAND PHARMACEUTICALS INC reported the six months ended June 30, 2023 results: revenue Total revenues for the six months ended June 30, 2023 were $70.3 million., net income Net income from continuing operations for the six months ended June 30, 2023 was $45.9 million, or $2.57 per diluted sha, EPS $2.57 per diluted share. Guidance reaffirmed.","evidence_excerpt":"Ligand Pharmaceuticals Incorporated (the “Company”) issued a press release announcing its financial results for the three and six months ended June 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/886163/000088616323000047/0000886163-23-000047-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the six months ended June 30, 2023"},{"label":"Revenue","value":"Total revenues for the six months ended June 30, 2023 were $70.3 million."},{"label":"Net income","value":"Net income from continuing operations for the six months ended June 30, 2023 was $45.9 million, or $2.57 per diluted sha"},{"label":"EPS","value":"$2.57 per diluted share"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"12b1fefcd69406e8063e067cab168643bcc7800e","claim":"LIGAND PHARMACEUTICALS INC reported the three and six months ended June 30, 2023 results: revenue Total revenues for the second quarter of 2023 were $26.4 million., net income Net income from continuing operations for the second quarter of 2023 was $2.3 million, or $0.13 per diluted share, EPS $0.13 per diluted share. Guidance reaffirmed.","evidence_excerpt":"Ligand Pharmaceuticals Incorporated (the “Company”) issued a press release announcing its financial results for the three and six months ended June 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/886163/000088616323000047/0000886163-23-000047-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three and six months ended June 30, 2023"},{"label":"Revenue","value":"Total revenues for the second quarter of 2023 were $26.4 million."},{"label":"Net income","value":"Net income from continuing operations for the second quarter of 2023 was $2.3 million, or $0.13 per diluted share"},{"label":"EPS","value":"$0.13 per diluted share"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}